Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galcanezumab for Trigeminal and Glossopharyngeal Pain in Small Fiber Neuropathy
NCT04158752Phase 4Completed
- Sponsor
- Duke University
- Start
- Jul 2020
- Primary completion
- Jan 2023
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of galcanezumab in trigeminal neuralgia (TN) and glossopharyngeal neuralgia (GPN), sponsored by Duke University. Primary endpoints: Change in Pain Score at 180 days, Number of Participants With a Change in Use of Anti-pain Medication at 135 days and 1 more. Started Jul 2020; status: completed.
02
Drugs
galcanezumab
03
Conditions
trigeminal neuralgia (TN)glossopharyngeal neuralgia (GPN)
Beyond the preview
Go deeper on NCT04158752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04158752.